Over-prescription of short-acting ß<sub>2</sub>-agonists for asthma in South Africa: Results from the SABINA III study.

Smith, C; Ambaram, A; Mitha, E; Abdullah, I; Abdullah, I A; Reddy, J; Trokis, J; Ramlachan, P; Govind, U; Lightfoot, K; Moodley, K; Smit, R; Beekman, M J H I

Over-prescription of short-acting ß₂-agonists for asthma in South Africa: Results from the SABINA III study.

Smith, C; Ambaram, A; Mitha, E; Abdullah, I; Abdullah, I A; Reddy, J; Trokis, J; Ramlachan, P; Govind, U; Lightfoot, K; Moodley, K; Smit, R; Beekman, M J H I.

Afiliação

Smith C; Morningside Mediclinic Private Hospital, Johannesburg, South Africa.
Ambaram A; Gateway Centre for Respiratory and Gastrointestinal Disease, Durban, South Africa.
Mitha E; Newgate Centre, Johannesburg, South Africa.
Abdullah I; Gatesville Medical Centre, Cape Town, South Africa.
Abdullah IA; Netcare St Augustine's Hospital, Bulwer, KwaZulu-Natal, South Africa.
Reddy J; Stanger Manor, KwaZulu-Natal, South Africa.
Trokis J; Windsor Park, Cape Town, South Africa.
Ramlachan P; Newkwa Medical Centre, Newlands, KwaZulu-Natal, South Africa.
Govind U; Randles Road Medical Centre, Durban, KwaZulu-Natal, South Africa.
Lightfoot K; AstraZeneca, Johannesburg, South Africa.
Moodley K; AstraZeneca, Johannesburg, South Africa.
Smit R; AstraZeneca, Johannesburg, South Africa.
Beekman MJHI; AstraZeneca, The Hague, The Netherlands.